A US pharmaceutical company, which is developing drugs to treat low sexual desire in women, has revealed that they have reached an impasse with the Food and Drug Administration over its drug, flibanserin.
Since women's sexual issues are more psychological, than physical, Sprout Pharmaceuticals said that the drug works by acting on brain chemicals connected to mood and appetite, Fox News reported.
Despite of women suffering from hypoactive sexual desire disorder reporting boost in sexual desire and reduction in stress with the drugs, the FDA has twice rejected flibanserin since 2010.
Cindy Whitehead, Sprout's chief operating officer, said that there are now
24 drugs for men for either testosterone replacement or erectile dysfunction, yet there are zero drugs for the most common form of sexual dysfunction in women.
The US firm acquired flibanserin from a German drugmaker in 2011, after they abandoned development of the daily pill following an FDA rejection.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app